1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Reymond N, Riou P and Ridley AJ: Rho
GTPases and cancer cell transendothelial migration. Methods Mol
Biol. 827:123–142. 2012. View Article : Google Scholar
|
5
|
Garcia-Mata R, Boulter E and Burridge K:
The ‘invisible hand’: regulation of RHO GTPases by RHOGDIs. Nat Rev
Mol Cell Biol. 12:493–504. 2011. View
Article : Google Scholar : PubMed/NCBI
|
6
|
Cho HJ, Baek KE and Yoo J: RhoGDI2 as a
therapeutic target in cancer. Expert Opin Ther Targets. 14:67–75.
2010. View Article : Google Scholar
|
7
|
Agarwal NK, Chen CH, Cho H, Boulbes DR,
Spooner E and Sarbassov DD: Rictor regulates cell migration by
suppressing RhoGDI2. Oncogene. 32:2521–2526. 2013. View Article : Google Scholar
|
8
|
Griner EM and Theodorescu D: The faces and
friends of RhoGDI2. Cancer Metastasis Rev. 31:519–528. 2012.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Yi B, Hu Y, Qin G, et al: Depletion of
RhoGDI2 expression inhibits the ability of invasion and migration
in pancreatic carcinoma. Int J Mol Med. 34:205–212. 2014.PubMed/NCBI
|
10
|
Rhim AD, Mirek ET, Aiello NM, et al: EMT
and dissemination precede pancreatic tumor formation. Cell.
148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kevans D, Wang LM, Sheahan K, et al:
Epithelial-mesenchymal transition (EMT) protein expression in a
cohort of stage II colorectal cancer patients with characterized
tumor budding and mismatch repair protein status. Int J Surg
Pathol. 19:751–760. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Matsuoka J, Yashiro M, Doi Y, et al:
Hypoxia stimulates the EMT of gastric cancer cells through
autocrine TGFβ signaling. PLoS One. 8:e623102013. View Article : Google Scholar
|
13
|
Burgess DJ: Breast cancer: Circulating and
dynamic EMT. Nat Rev Cancer. 13:1482013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Nitz MD, Harding MA and Theodorescu D:
Invasion and metastasis models for studying RhoGDI2 in bladder
cancer. Methods Enzymol. 439:219–233. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Li X, Wang J, Zhang X, Zeng Y, Liang L and
Ding Y: Overexpression of RhoGDI2 correlates with tumor progression
and poor prognosis in colorectal carcinoma. Ann Surg Oncol.
19:145–153. 2012. View Article : Google Scholar
|
16
|
Scherle P, Behrens T and Staudt LM:
Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding
protein, is expressed preferentially in lymphocytes. Proc Natl Acad
Sci USA. 90:7568–7572. 1993. View Article : Google Scholar : PubMed/NCBI
|
17
|
Niu H, Li H, Xu C and He P: Expression
profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung
cancer metastasis. Oncol Rep. 24:465–471. 2010.PubMed/NCBI
|
18
|
Cho HJ, Baek KE, Kim IK, et al:
Proteomics-based strategy to delineate the molecular mechanisms of
RhoGDI2-induced metastasis and drug resistance in gastric cancer. J
Proteome Res. 11:2355–2364. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Theodorescu D, Sapinoso LM, Conaway MR,
Oxford G, Hampton GM and Frierson HF Jr: Reduced expression of
metastasis suppressor RhoGDI2 is associated with decreased survival
for patients with bladder cancer. Clin Cancer Res. 10:3800–3806.
2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Ma L, Xu G, Sotnikova A, et al: Loss of
expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in
Hodgkin lymphoma. Br J Haematol. 139:217–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
Dovas A and Couchman JR: RhoGDI: multiple
functions in the regulation of Rho family GTPase activities.
Biochem J. 390:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
DerMardirossian C and Bokoch GM: GDIs:
central regulatory molecules in Rho GTPase activation. Trends Cell
Biol. 15:356–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
23
|
Hart MJ, Maru Y, Leonard D, Witte ON,
Evans T and Cerione RA: A GDP dissociation inhibitor that serves as
a GTPase inhibitor for the Ras-like protein CDC42Hs. Science.
258:812–815. 1992. View Article : Google Scholar : PubMed/NCBI
|
24
|
Chuang TH, Xu X, Knaus UG, Hart MJ and
Bokoch GM: GDP dissociation inhibitor prevents intrinsic and GTPase
activating protein-stimulated GTP hydrolysis by the Rac GTP-binding
protein. J Biol Chem. 268:775–778. 1993.PubMed/NCBI
|
25
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Theys J, Jutten B, Habets R, et al:
E-Cadherin loss associated with EMT promotes radioresistance in
human tumor cells. Radiother Oncol. 99:392–397. 2011. View Article : Google Scholar : PubMed/NCBI
|